PDF herunterladen
Aktuelle Neurologie 2014; 41(03): 146-155
DOI: 10.1055/s-0034-1369926
Übersicht
© Georg Thieme Verlag KG Stuttgart · New York

Praktische Anwendung der neuen Antikoagulanzien bei Patienten mit TIA und Schlaganfall und Vorhofflimmern bei absoluter Arrhythmie

Practical Use of Novel Anticoagulants in Patients with TIA or Stroke and Atrial Fibrillation
H. C. Diener
1   Universitätsklinik für Neurologie und Schlaganfallzentrum, Essen
,
R. Veltkamp
2   Department of Stroke Medicine, Imperial College, London
6   Neurologische Universitätsklinik, Heidelberg
,
M. Grond
3   Klinik für Neurologie und Neurogeriatrie, Kreisklinikum Siegen
,
M. Dichgans
4   Institut für Schlaganfall- und Demenzforschung und Interdisziplinäres Schlaganfallzentrum, Klinikum der Universität München
,
M. Endres
5   Klinik und Hochschulambulanz für Neurologie, Charité – Universitätsmedizin Berlin
,
C. Weimar
1   Universitätsklinik für Neurologie und Schlaganfallzentrum, Essen
,
B. Frank
1   Universitätsklinik für Neurologie und Schlaganfallzentrum, Essen
,
W. Hacke
6   Neurologische Universitätsklinik, Heidelberg
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
24. März 2014 (online)

Auch verfügbar auf
    Lizenzen und Reprints

Erratum zu diesem Artikel:

Praktische Anwendung der neuen Antikoagulanzien bei Patienten mit TIA und Schlaganfall und Vorhofflimmern bei absoluter ArrhythmieAktuelle Neurologie 2014; 41(03): e42-e42
DOI: 10.1055/s-0033-1336971

Zusammenfassung

Die direkten oralen Antikoagulanzien (DOAK) Apixaban, Dabigatran, Edoxaban und Rivaroxaban stellen eine Alternative zu Vitamin-K-Antagonisten (VKA) für die Prävention von Schlaganfällen bei Patienten mit Vorhofflimmern dar. Sie werden in fester oraler Dosierung angewandt und es besteht keine Notwendigkeit eines regelmäßigen Gerinnungsmonitorings. In der Sekundärprävention nach TIA und ischämischem Insult sind DOAK mindestens genauso wirksam wie eine Antikoagulation mit Warfarin. Das Risiko für intrazerebrale Blutungen ist um 40 – 70 % geringer als bei VKA. Für den klinischen Alltag gibt es jedoch eine Vielzahl von Fragen, die durch die aktuellen Studien nicht beantwortet werden. Der ideale Zeitpunkt des Beginns einer oralen Antikoagulation mit DOAK nach TIA und Schlaganfall ist nicht bekannt, da in den randomisierten Studien alle Patienten mit frischen zerebralen ischämischen Ereignissen ausgeschlossen wurden. Eine effektive Antikoagulation mit VKA und DOAK stellt derzeit eine Kontraindikation für die systemische Thrombolyse dar. Bisher gibt es keine prospektiv erhobenen Daten zur Behandlung von zerebralen Blutungen unter DOAK. Spezifische Antidots sind in Entwicklung. Diese Übersicht diskutiert zudem den Einsatz von DOAK bei Patienten mit kognitiven Einschränkungen, Gefahr von Stürzen, symptomatischer Karotisstenose, Nierenfunktionsstörungen, tiefen Beinvenenthrombosen und Lungenembolien. Außerdem werden prospektive Register und neue Indikationen in der Neurologie beschrieben.

Abstract

The direct oral anticoagulants (DOAC) apixaban, dabigatran, edoxaban and rivaroxaban are alternative treatment options to vitamin K antagonists (VKA) for the prevention of stroke in patients with atrial fibrillation. DOAC are given in a fixed oral dose and regular coagulation monitoring is not required. DOAC are at least as effective as warfarin in secondary stroke prevention in patients with atrial fibrillation who have had a TIA or ischemic stroke. The risk of intracranial bleeds is reduced by 40 – 70 % compared with VKA. The use of the DOAC in clinical routine leaves many questions open which were not addressed in the randomized trials. The best point of time to initiate anticoagulation after an acute ischemic stroke is unknown since patients with a recent stroke were excluded from the randomized trials. Effective anticoagulation with VKA or DOAC is a contraindication for systemic thrombolysis in acute stroke. No controlled trials on the treatment of cerebral hemorrhages in patients treated with DOAC have yet been carried out. Specific antidotes for DOAC are under development. This review addresses the use of DOAC in patients with cognitive impairment, increased risk of falls, symptomatic carotid stenosis, kidney failure, deep vein thrombosis and pulmonary embolism. Furthermore, prospective registries and new indications for DOAC in neurology are described.

Schlüsselwörter

Vorhofflimmern - Schlaganfall - Vitamin-K-Antagonisten - direkte orale Antikoagulanzien - intrakranielle Blutungen

Keywords

atrial fibrillation - stroke - vitamin-K antagonists - direct oral anticoagulants - intracranial bleeds
 

  • Literatur

  • 1 Hart R, Benavente O, McBride R et al. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 1999; 131: 492-501
    PubMedGoogle Scholar
  • 2 Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146: 857-867
    CrossrefPubMedGoogle Scholar
  • 3 European Atrial Fibrillation Trial (EAFT) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993; 342: 1255-1262
    CrossrefPubMedGoogle Scholar
  • 4 Heidbuchel H, Verhamme P, Alings M et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 2013; 15: 625-651
    CrossrefPubMedGoogle Scholar
  • 5 Connolly SJ, Eikelboom J, Joyner C et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011; 364: 806-817
    CrossrefPubMedGoogle Scholar
  • 6 Easton JD, Lopes RD, Bahit MC et al. Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial. Lancet Neurol 2012; 11: 503-511
    CrossrefPubMedGoogle Scholar
  • 7 Connolly SJ, Ezekowitz MD, Yusuf S et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151
    CrossrefPubMedGoogle Scholar
  • 8 Diener HC, Connolly SJ, Ezekowitz MD et al. Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. Lancet Neurol 2010; 9: 1157-1163
    CrossrefPubMedGoogle Scholar
  • 9 Giugliano RP, Ruff CT, Braunwald E et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369: 2093-2104
    CrossrefPubMedGoogle Scholar
  • 10 Patel MR, Mahaffey KW, Garg J et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883-891
    CrossrefPubMedGoogle Scholar
  • 11 Hankey GJ, Patel MR, Stevens SR et al. Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. Lancet Neurol 2012; 11: 315-322
    CrossrefPubMedGoogle Scholar
  • 12 Mazya MV, Lees KR, Markus R et al. Safety of intravenous thrombolysis for ischemic stroke in patients treated with warfarin. Ann Neurol 2013; Jun 6; DOI: 10.1002/ana23924.
    PubMedGoogle Scholar
  • 13 Xian Y, Liang L, Smith EE et al. Risks of intracranial hemorrhage among patients with acute ischemic stroke receiving warfarin and treated with intravenous tissue plasminogen activator. JAMA 2012; 307: 2600-2608
    Google Scholar
  • 14 Hacke W, Furlan AJ. (Here comes that) razors edge. Endovascular stroke therapy: the end, or only the beginning?. Int J Stroke 2013; 8: 331-333
    CrossrefPubMedGoogle Scholar
  • 15 Hart RG, Diener HC, Yang S et al. Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial. Stroke 2012; 43: 1511-1517
    CrossrefPubMedGoogle Scholar
  • 16 Diener HC, Easton JD, Hankey GJ et al. Novel oral anticoagulants in secondary prevention of stroke. Best practice & research Clinical haematology 2013; 26: 131-139
    CrossrefPubMedGoogle Scholar
  • 17 Steiner T, Böhm M, Laufs U et al. Neue direkte orale Antikoagulantien: was im Notfall zu beachten ist. Deutsches Ärzteblatt 2012; 109: A1928-1930
    PubMedGoogle Scholar
  • 18 Walenga JM, Adiguzel C. Drug and dietary interactions of the new and emerging oral anticoagulants. Int J Clin Pract 2010; 64: 956-967
    CrossrefPubMedGoogle Scholar
  • 19 Stangier J, Clemens A. Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor. Clin Appl Thromb Hemost 2009; 15 (Suppl. 01) 9S-16S
    CrossrefPubMedGoogle Scholar
  • 20 Flaker GC, Belew K, Beckman K et al. Asymptomatic atrial fibrillation: demographic features and prognostic information from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Am Heart J 2005; 149: 657-663
    CrossrefPubMedGoogle Scholar
  • 21 Smith E, Rosand J, Knudsen K et al. Leukoaraiosis is associated with warfarin-related hemorrhage following ischemic stroke. Neurology 2002; 59: 193-197
    CrossrefPubMedGoogle Scholar
  • 22 Lou M, Al-Hazzani A, Goddeau Jr RP et al. Relationship between white-matter hyperintensities and hematoma volume and growth in patients with intracerebral hemorrhage. Stroke 2010; 41: 34-40
    CrossrefPubMedGoogle Scholar
  • 23 Charidimou A, Kakar P, Fox Z et al. Cerebral microbleeds and recurrent stroke risk: systematic review and meta-analysis of prospective ischemic stroke and transient ischemic attack cohorts. Stroke 2013; 44: 995-1001
    CrossrefPubMedGoogle Scholar
  • 24 Poli D, Antonucci E, Testa S et al. Bleeding risk in very old patients on vitamin K antagonist treatment: results of a prospective collaborative study on elderly patients followed by Italian Centres for Anticoagulation. Circulation 2011; 124: 824-829
    CrossrefPubMedGoogle Scholar
  • 25 Gage BF, Birman-Deych E, Kerzner R et al. Incidence of intracranial hemorrhage in patients with atrial fibrillation who are prone to fall. Am J Med 2005; 118: 612-617
    CrossrefPubMedGoogle Scholar
  • 26 Wylie EJ, Hein MF, Adams JE. Intracranial hemorrhage following surgical revascularization for treatment of acute strokes. J Neurosurg 1964; 21: 212-215
    CrossrefPubMedGoogle Scholar
  • 27 Armstrong MJ, Gronseth G, Anderson DC et al. Summary of evidence-based guideline: periprocedural management of antithrombotic medications in patients with ischemic cerebrovascular disease: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 2013; 80: 2065-2069
    CrossrefPubMedGoogle Scholar
  • 28 Liapis CD, Bell PR, Mikhailidis D et al. ESVS guidelines. Invasive treatment for carotid stenosis: indications, techniques. Eur J Vasc Endovasc Surg 2009; 37: 1-19
    PubMedGoogle Scholar
  • 29 Sattari M, Lowenthal DT. Novel oral anticoagulants in development: Dabigatran, Rivaroxaban, and Apixaban. American journal of therapeutics 2011; 18: 332-338
    CrossrefPubMedGoogle Scholar
  • 30 Camm AJ, Lip GY, De Caterina R et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation – developed with the special contribution of the European Heart Rhythm Association. Europace 2012; 14: 1385-1413
    CrossrefPubMedGoogle Scholar
  • 31 Olesen JB, Lip GY, Kamper AL et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med 2012; 367: 625-635
    CrossrefPubMedGoogle Scholar
  • 32 Weimar C, Benemann J, Katsarava Z et al. Adherence and quality of oral anticoagulation in cerebrovascular disease patients with atrial fibrillation. Eur Neurol 2008; 60: 142-148
    CrossrefPubMedGoogle Scholar
  • 33 Kakkar AK, Mueller I, Bassand JP et al. Risk profiles and antithrombotic treatment of patients newly diagnosed with atrial fibrillation at risk of stroke: Perspectives from the international, observational, prospective GARFIELD registry. PLoS One 2013; 8: e63479
    CrossrefPubMedGoogle Scholar
  • 34 Nieuwlaat R, Capucci A, Lip GY et al. Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Survey on Atrial Fibrillation. Eur Heart J 2006; 27: 3018-3026
    CrossrefPubMedGoogle Scholar
  • 35 Hart RG, Diener HC, Coutts S et al. for the Cryptogenic/ESUS International Working Group. Embolic strokes of undetermined source: the case for a new clinical construct. Lancet Neurology 2014; 13: 429-438
    CrossrefPubMedGoogle Scholar